✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Drug Reference

Dulaglutide

Released: Last reviewed:

Weekly GLP-1 receptor agonist. Brand name: Trulicity. FDA-approved for type 2 diabetes mellitus.

By Eli Lilly
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Dulaglutide overview

Weekly GLP-1 receptor agonist. Brand name: Trulicity. FDA-approved for type 2 diabetes mellitus.

Dulaglutide at a glance

Manufacturer
Eli Lilly
FDA status
FDA-approved

Related pages

Key facts, checked November 20, 2026

Trulicity (dulaglutide) is a once-weekly injection. Its Trulicity label covers blood-sugar control in adults and children 10 and older with type 2 diabetes, and lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and heart disease or several risk factors. It is not approved for weight management. FDA’s November 9, 2026 safety communication requires every approved GLP-1 label, including dulaglutide’s, to add a warning about NAION, a sudden loss of vision in one eye. No telehealth program we score lists dulaglutide as a weight-loss option.